Land: Armenien
Sprache: Englisch
Quelle: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
propofol
B.Braun Melsungen AG
propofol
10mg/ml
emulsion for i/v injection
Prescription
Propofol l0 mg Excipients rryith known effect: 200 mg 500 mg I ml emulsion for injection or infusion contains Soya-bean oil, refined 50 mg Sodium 0.03 mg For the full list ofexcipients, see section 6.1. 4.1 Therapeuticindications Propofol-Lipuro l0 mg/ml is a short-acting intravenous general anaesthetic for o inductibn and maintenance ofgeneral anaesthesia in adults and children > I month o sedation ofventilated patients->l6 years ofage in the intensive care unit - o sedation for diagnostii and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > I month. 4.2 Posolory and Method of Administration General instructions propofol-Lipuro l0 mg/ml must only be given in hospitals or adequately equipped day therapy units Uy physicians trained in anaesthesia or in the care of patients in intensive care. Circulatory and respi- .atory functions should be constantly monitored (e.g. ECG, pulse-oxymeter) and facilities for mainte- nance ofpatent airways, artificial ventilation, and other resuscitation facilities should be immediately available at all times. For sedation during surgical or diagnostic procedures Propofol-Lipuro l0 mg/ml shotrld not be given by the same person that carries out the surgical or diagnostic procedure. Supplementary analgesic medicinal products are generally required in addition to Propofot-Lipuro l0 mg/ml. - B. Bdun Mcbngo AC rDE- Posologlt Propofol-Lipuro l0 mg/ml is given intravenously. The dosage is adjusted individually according to the patient's response. o General anaesthesia in adults Induction of anaesthesia: For induction of anaesthesia Propofol-Lipuro I 0 mg/ml should be titrated (20 - 40 mg of propofol every l0 seconds) against the patient's response until the clinical signs show the onset ofanaesthesia. Most adult patients younger than 55 years are likely to require 1.5 to 2.5 mg/kg body weight. In patients over this age and in patients of ASA grades III and IV, especially those with impaired car- diac function, the dosage requirements r Lesen Sie das vollständige Dokument